UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

November 26, 2021

The combination of cabozantinib and atezolizumab led to a statistically significant improvement in progression-free survival and a numerical improvement in overall survival vs sorafenib as frontline treatment in patients with advanced hepatocellular carcinoma, according to findings from the first planned analysis of the phase 3 COSMIC-312 trial.

November 16, 2021

The Cancer Cell Map Initiative, developed by investigators at the University of California San Francisco and the University of California San Diego, has successfully charted how hundreds of genetic mutations involved in breast cancer and cancers of the head and neck affect the activity of proteins that ultimately lead to disease.

October 25, 2021

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

October 19, 2021

Hope S. Rugo, MD, FASCO, provides her insights on the final analysis data from the international phase 3 ASCENT trial.

September 28, 2021

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

September 28, 2021

Hope S. Rugo, MD, discusses the final data from the phase 3 KEYNOTE-355 trial with pembrolizumab plus chemotherapy in patients with metastatic TNBC and the clinical impact on the treatment paradigm.

September 24, 2021

Nina Shah, MD, discusses key findings from the phase 2 KarMMA trial in relapsed/refractory multiple myeloma.

September 15, 2021

Nina Shah, MD, discusses the current state of cellular therapy in multiple myeloma.

September 15, 2021

Nina Shah, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

September 10, 2021

Thomas G. Martin, MD, discusses the potential utility of quadruplet-based regimens in relapsed/refractory multiple myeloma.

September 05, 2021

Triplet regimens leveraging novel agents targeted at overcoming mechanisms of resistance in combination with immune checkpoint inhibitors and anti-angiogenic therapies represent the next frontier in hepatocellular carcinoma.

August 26, 2021

Acquired resistance to endocrine therapy has presented challenges for patients with hormone receptor–positive breast cancer.

July 29, 2021

Updated overall survival data from the APACT trial suggest improved outcomes for patients with resected pancreatic cancer who receive adjuvant nab-paclitaxel plus gemcitabine despite missing the primary end point in earlier analysis.

July 21, 2021

The investigational therapy ficlatuzumab in combination with cytarabine demonstrated encouraging clinical efficacy with favorable tolerability when used as a treatment in patients with high-risk acute myeloid leukemia.

July 20, 2021

Thomas G. Martin, MD, discusses the latest news in frontline, early relapsed, and heavily pretreated multiple myeloma, including the growing promise of quadruplets, emerging targets beyond BCMA, and the potential emergence of quadruplets, venetoclax, and antiviral therapy in amyloidosis.

June 28, 2021

Thomas G. Martin, MD, speaks to the FDA approval of isatuximab, carfilzomib, and dexamethasone, and potential future directors for isatuximab.

June 21, 2021

May 25, 2021

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

May 10, 2021

Nina Shah, MD, discusses the newfound role of BCMA-directed CAR T-cell therapies in multiple myeloma, how the field may select between ide-cel and cilta-cel if the latter is approved, and novel cellular therapies in clinical development.

April 28, 2021

Nina Shah, MD, discusses the efficacy and safety data observed with ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.